June 10, 2014
ARLINGTON, Va. — HDMA President and CEO John M. Gray released the following statement on today's passage of the Ensuring Patient Access and Effective Drug Enforcement Act of 2014 (H.R. 4709) — sponsored by Reps. Tom Marino (R-Pa.), Marsha Blackburn (R-Tenn.), Peter Welch (D-Vt.) and Judy Chu (D-Calif.) — by the House Energy and Commerce Committee.
“The House Energy and Commerce Committee's vote today demonstrates the importance of this critical, bipartisan legislation, and its ability to foster greater collaboration and transparency between supply chain stakeholders and federal regulators to address prescription drug abuse and diversion. The bill will allow companies registered with the Drug Enforcement Administration (DEA) to submit corrective action plans to address DEA concerns, and clarify key terminology in the Controlled Substances Act to better delineate registrant responsibilities under the law.“HDMA and the nation’s primary healthcare distributors will continue to work with supply chain stakeholders and Reps. Marino, Blackburn, Welch and Chu to ensure passage of this important legislation.”
HDA is the national association representing primary healthcare distributors, the vital link between the nation’s pharmaceutical manufacturers and healthcare providers. Each business day, HDA member companies ensure that over 15 million prescription medicines and healthcare products are delivered safely and efficiently to more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. HDA and its members work daily to provide value and achieve cost savings, an estimated $42 billion each year to our nation’s healthcare system.